SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance
Tu, YanyangNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationWang, Zhen, Xiaoshan Xu, Nan Liu, Yingduan Cheng, Weilin Jin, Pengxing Zhang, Xin Wang, Hongwei Yang, Hui Liu, and Yanyang Tu. 2018. “SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance.” Oncotarget 9 (1): 192-204. doi:10.18632/oncotarget.22773. http://dx.doi.org/10.18632/oncotarget.22773.
AbstractGlioblastoma multiforme (GBM) is the most common and aggressive brain tumor with limited therapeutic options. Glioma stem cell (GSC) is thought to be greatly responsible for glioma tumor progression and drug resistance. But the molecular mechanisms of GSC deriving recurrence and drug resistance are still unclear. SOX9 (sex-determining region Y (SRY)-box9 protein), a transcription factor expressed in most solid tumors, is reported as a key regulator involved in maintaining cancer hallmarks including the GSCs state. Previously, we have observed that silencing of SOX9 suppressed glioma cells proliferation both in vitro and in vivo. Here, we found that SOX9 was essential for GSC self-renewal. Silencing of SOX9 down-regulated a broad range of stem cell markers and inhibited glioma cell colony and sphere formation. We identified pyruvate dehydrogenase kinase 1 (PDK1) as a target gene of SOX9 using microarray analyses. PDK1 inactivation greatly inhibited glioma cell colony and sphere formation and sensitized glioma spheres to temozolomide (TMZ) toxicity. In addition, SOX9-shRNA and PDK1 inhibitor could greatly sensitize GSC to TMZ in vivo. Taken together, our data reveals that SOX9-PDK1 axis is a key regulator of GSC self-renewal and GSC temozolomide resistance. These findings may provide help for future human GBM therapy.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:35014413
- HMS Scholarly Articles